NanoViricides Highlights Broad-Spectrum Antiviral NV-387 Amid Ebola Outbreak
NanoViricides underscores the potential of its oral drug candidate NV-387 as a pandemic preparedness tool amid the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda.
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has drawn attention to its broad-spectrum antiviral candidate NV-387 in light of the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain, emphasizing NV-387’s proposed mechanism targeting viral cell attachment pathways common across filoviruses. This positions the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.
The announcement comes as health authorities work to contain the outbreak, highlighting the need for effective treatments against emerging viral diseases. NanoViricides’ lead drug candidate, NV-387, is designed as a broad-spectrum antiviral that the company plans to develop for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company’s other advanced candidate, NV-HHV-1, targets shingles.
NanoViricides’ platform technology is based on TheraCour nanomedicine technology, which the company licenses from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license for several drugs with specific targeting mechanisms for treating human viral diseases including HIV/AIDS, hepatitis B and C, rabies, herpes simplex, varicella-zoster, influenza, Asian bird flu, dengue, Japanese encephalitis, West Nile, Ebola/Marburg, and certain coronaviruses.
The company noted that NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, while NV-CoV-2-R encapsulates remdesivir within its polymeric micelles. NanoViricides believes that since remdesivir is already FDA-approved, the latter candidate could be approvable if safety is comparable. Remdesivir is developed by Gilead.
As a clinical-stage company, NanoViricides cautioned that drug development is extremely lengthy and requires substantial capital. There can be no assurance that any of its pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development or lead to a successful product. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/mm3Z5.